pharmaceuticals — Lanton Law Blog

Lanton Law Quoted in Pharmacy Times Interview on Drug Pricing Reforms Amid the Repeal of Executive Order 14087

Lanton Law was quoted in the Pharmacy Times Article titled "Reversal of Executive Order (EO) 14087 Raises Questions About Future Drug Pricing Reforms.” We discuss the EO and how pharmacists are impacted. The article can be viewed here.

healthcare, FDA, CMS, life sciences, Medicare, pharmacy, pharmaceuticals, pharmacy benefit manager, Pharmacy Times, PhRMARon LantonJanuary 28, 2025Executive Order 14087, drug pricing, Inflation Reduction Act, HHS, FDA, biosimilars, oncology, Medicare, CMS, pharmacy, PhRMA, PBM

FTC, DOJ and HHS Extend RFI on Private Equity Control in Health Care Markets

The Federal Trade Commission, the Department of Justice’s (DOJ) Antitrust Division, and the U.S. Department of Health and Human Services (HHS) are extending the deadline by 30 days for the public to comment on a tri-agency Request for Information (RFI) examining private-equity and other corporations’ increasing control over health care markets. The new deadline is now June 5, 2024.

healthcare, hospitals, IoT, HealthIT, LTC, life sciences, Long term care pharmacy, pharmaceuticals, PhRMA, private equity, SPAC, technologyRon LantonMay 2, 2024private equity firms, private equity, FTC, HHS, DOJ, RFI

CMS Makes An Impactful Change Regarding Biosimilars

Within its final calendar year 2025 Medicare Advantage and Part D final rule seen here, the Centers for Medicare and Medicaid Servces (CMS) is allowing Part D sponsors the ability to make midyear substitutions of biosimilars for their reference products on their formularies.

biologics, Biosimilars, biotechnology, biotech, healthcare, insurance, pharmaceuticalsRon LantonApril 8, 2024biosimilars, CMS, Centers for Medicare and Medicaid Services, insurance, healthcare

Lanton Law Speaks With Pharmacy Times About Provider Status

Below is the description from Pharmacy Times about our discussion with them on pharmacy provider status. You can listen to the interview here.

CMS, healthcare, pharmaceuticals, pharmacyRon LantonOctober 6, 2023pharmacy, pharmacy provider status, collaborative agreement, reimbursement, New England, Massachusetts, Michigan

New York Proposes New PBM Regulations

The New York State Department of Financial Services has proposed new rules surrounding pharmacy benefit managers (PBMs) that deal with establishing definitions; licensing; contracting with pharmacies; acquisition of PBMs; consumer protections and audit regulations regarding PBMs.

healthcare, Medicare Part D, pharmaceuticals, pharmacy, pharmacy benefit managerRon LantonAugust 29, 2023Pharmacy Benefit Manager, New York, PBM, pharmacy, insurance, licensure, audit, contracting, mergers and acquisitions, regulation

Biden Administration Announces First Ten Drugs Selected for Medicare Price Negotiation

The Biden Administration has announced today that Medicare will be able to negotiate drug prices for the first time due to provisions within the Inflation Reduction Act.

healthcare, life sciences, Medicare Part D, pharmaceuticals, prescription drug costsRon LantonAugust 29, 2023Inflation Reduction Act, drug prices, pharmaceuticals, prescription drug prices, Medicare Part D, CMS, HHS

Pharmacy Congressional Bills to Watch

Two pro-pharmacy bills continue to make their way through Congress.

healthcare, insurance, pharmaceuticals, pharmacy, pharmacy benefit managerRon LantonAugust 19, 2023Medicaid, Congress, pharmacy, retail pharmacy, any willing provider

More Drugmakers Sue Biden Administration Over Medicare Negotiation

Johnson and Johnson has filed a lawsuit in New Jersey federal district court, arguing that the new powers granted to Medicare to negotiate drug prices violates the First and Fifth Amendments of the U.S. Constitution. Medicare’s new power to negotiate comes from the recently enacted Inflation Reduction Act (IRA). Earlier suits by Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA have made similar arguments.

Lanton Law Quoted in Pharmacy Times Article Titled "Mifepristone Has its Day in Court"

Lanton Law was quoted in Pharmacy Times article titled “Mifepristone Has its Day in Court.” The article discusses the drug amid its backdrop in the U.S. Supreme Court.

healthcare, pharmacy, pharmaceuticalsRon LantonJuly 14, 2023Mifepristone, US Supreme Court, SCOTUS, FDA

Lanton Law Lobbies on Beacon Hill in Boston, Massachusetts for Pharmacy Issues

Lanton Law was on Beacon Hill this week advocating for pharmacy issues.

lobbyist, healthcare, health system, pharmaceuticals, pharmacyRon LantonJuly 14, 2023Beacon Hill, Boston, legislation, legislative, Massachusetts statehouse, pharmacy, health promotion screening, Pharmacy Benefit Manager Transparency Act

Lanton Law Teams Up With MSHP on Health Promotion Screening Bill

On behalf of the Massachusetts Society of Health-System Pharmacists, we wrote an article advocating for the importance of health promotion screening in Massachusetts.

healthcare, pharmaceuticals, pharmacyRon LantonApril 27, 2023health promotion screening, pharmacy provider status, Pharmacy Times, Massachusetts Society of Health System Pharmacists

Lanton Law Speaks at Summit & Reverse Expo

We were pleased to be invited to Orlando, Florida to speak with IDN with our presentation titled “Price, Innovation & Policy: What’s on the Horizon for the Industry.

Congressional Bill Advocating for Biosimilars and Generics Introduced

U.S. Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT) have introduced the Affordable Prescriptions for Patients Act. The bill seen here seeks to lower drug prices by preventing bad actors’ anti-competitive use of patents to block generic and biosimilar competition from coming to market. The bill addresses two important issues such as product hopping and the patent dance.

Biosimilars, healthcare, life sciences, pharmaceuticalsRon LantonMarch 3, 2023Affordable Prescriptions for Patients Act, Congress, biosimilars, patent, generic drugs, patent thicket

FDA REMS Change for Abortion Pill Creates Opportunities, Questions for Pharmacists

Although the FDA has now allowed retail pharmacies to dispense mifepristone, a drug used for medicated abortions, questions still remain about the requirements for pharmacies and the availability of the drug. Lanton Law talks to Pharmacy Times in an interview about a post Dobbs world with mifepristone.

healthcare, pharmaceuticals, pharmacy, Pharmacy TimesRon LantonJanuary 12, 2023mifepristone, FDA, pharmacy, physicians, Dobbs v. Jackson Women’s Health, U.S. Supreme Court, REMS

Prescription Digital Therapeutics Bill Introduced in Congress

The Medicaid and CHIP Access to Prescription Digital Therapeutics Act also known as S. 5238 seen here was introduced on December 12, 2022 by Senator Capito (R-WV).

CMS, Congress, Digital Therapeutics, healthcare, HHS, HealthIT, legislation, pharmaceuticalsRon LantonDecember 27, 2022Medicaid and CHIP Access to Prescription Digital Therapeutics Act, digital therapeutics, remote patient therapy, remote patient monitoring, CMS, Medicaid, CHIP, prescription

Expert Discusses Long-Term Implications of Roe V. Wade Decision for Pharmacists, Contraception Access

In an interview with Pharmacy Times, Ron Lanton III, Esq, partner at Lanton Law, discussed the recent Supreme Court ruling on Dobbs v. Jackson Women’s Health and what this could mean for pharmacists. In the interview, Lanton said the decision leaves many things ambiguous, which will most likely result in litigation around the country in the coming weeks and months.

Pharmacy Times Speaks with Lanton Law About "Vanity Drugs"

In an interview by Aislinn Antrim of Pharmacy Times called “Calling Them ‘Vanity Drugs,’ Some Insurers Refuse to Cover New Anti-Obesity Drugs,” Ron Lanton III, Esq., Partner at Lanton Law, discussed why insurers are refusing to cover new, highly effective anti-obesity drugs and how some prescribers are getting around the issue. Lanton said that this is a common issue across many different disease spaces and drug types, but some policy changes may be able to help.

Pharmacy Transactions- The Buying and Selling of a Pharmacy

There are many things to consider when you are deciding to either purchase or sell a pharmacy. Hence the need for an experienced firm to address these matters.

Lanton Law has helped various stakeholders ranging from private equity to retail pharmacies who are looking to either acquire or divest either a retail or specialty pharmacy.

healthcare, pharmaceuticals, pharmacyRon LantonJune 23, 2022pharmacy, private equity firms, chain pharmacy, retail pharmacy, corporate governance, lease negotiation, regulatory, shareholder documents, employment agreement, strategic planning, business strategy

Lanton Law Podcast speaks with the Vermont Office of the Health Care Advocate

For this episode of the Lanton Law Podcast we interview Sam Peisch of the Vermont Office of the Health Care Advocate. We discuss the new Office of the Health Care Advocate within Vermont Legal Aid, healthcare challenges in the state as well as efforts to address healthcare inequity within at risk communities in Vermont.

health system, healthcare, legislature, pharmaceuticals, pharmacy, prescription drug costs, reimbursement, technology, telehealth, telemedicine, behavioral healthRon LantonJune 23, 2022Vermont, Vermont Office of the Health Care Advocate, Vermont Legal Aid, healthcare inequity, healthcare cost

FTC Takes Aggressive Policy Stance Against Drug Manufacturers and Pharmacy Benefit Managers (PBMs)

The Federal Trade Commission (FTC) has come out aggressively against both pharmaceutical manufacturers and pharmacy benefit managers (PBMs). The agency has released its policy statement seen here, announcing that the agency “will ramp up enforcement against any illegal bribes and rebate schemes that block patients’ access to competing lower-cost drugs.”